The contrast CT scan for kidney cancer — what it shows and why it decides so much

A contrast CT answers the questions that decide everything else. First, whether the mass takes up contrast dye — enhancement is what separates a solid tumour from a harmless cyst. Second, its size, where it sits in the kidney, and how close it is to the collecting system and the main blood vessels, which is what tells a surgeon whether the kidney can be spared. Third, whether there is anything beyond the kidney: enlarged lymph nodes, tumour extending into the renal vein, or a deposit elsewhere in the scanned area. It does not give a grade and it cannot confirm the cell type. Those come from tissue, if tissue is ever needed.

For characterising a kidney mass, yes — a CT done without contrast cannot answer the main question. Contrast dye travels in blood, so tissue with a blood supply brightens after the injection while plain fluid does not. That difference is the whole basis of the report. A scan done without contrast, or one done for a completely different reason such as a stone study, will often mention a mass without being able to say anything useful about it, which is why so many people are called back for a proper renal protocol scan. If iodinated contrast is not suitable for you, an MRI answers the same question a different way.

Often, yes — and this is genuinely different from most other cancers. A solid, clearly enhancing renal mass with typical features on a good-quality contrast CT is treated as a kidney cancer without tissue confirmation first, because a biopsy would rarely change what is done next. NCCN guidance supports imaging-led characterisation of a renal mass, with biopsy used selectively rather than routinely. That said, a CT cannot be certain. It cannot reliably tell a small cancer from some benign tumours, and it cannot give a grade. When the answer would change the plan — before ablation, before systemic treatment, or when a benign tumour is genuinely possible — a biopsy is done.

It is checked first, not assumed. Blood tests for creatinine and eGFR are done before the scan so the team knows what your kidneys are working with, and the decision is made on those numbers rather than on age or on the presence of a tumour. Where function is reduced, the options are a scan with careful hydration and a reduced dye load, an MRI instead, or a different sequence of tests altogether. The risk is real but it is manageable, and it is weighed against the cost of not knowing what the mass is. Tell the team about diabetes, dehydration, previous reactions to contrast and every medicine you take.

A routine abdominal CT usually takes one pass after contrast, timed for the liver and bowel. A renal mass protocol takes several: a non-contrast pass to establish a baseline, then passes as the dye reaches the kidneys, saturates the working tissue, and finally drains into the collecting system. Comparing the same slice across those passes is what shows whether a mass enhances and by how much, and the last pass maps the drainage system for surgical planning. This is why a mass spotted on a routine scan is so often rescanned. Nothing was missed — the first scan simply was not built to answer this question.

The images, not just the report line, are reviewed by a specialist, and the case is taken to a uro-oncology tumour board rather than decided by one doctor. If the mass looks benign you may simply be reassured or offered interval imaging. If it looks like a cancer, staging is completed and options are laid out with you before anything is booked. At CION the consultation, the bloods and the CT, ultrasound and MRI imaging are medical-oncology led and delivered in-house; surgery, ablation and PET-CT are coordinated with specialist urology, uro-oncology and interventional radiology partner centres. Bring the image files to your appointment, not only the printed report.